Related Experiment Video
Updated: May 23, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Current Pharmacological Management in Juvenile Huntington's Disease
Lisa Robertson1, Helen Santini, Kirsty L O'Donovan
1Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield UK S10 2TH; Neurogenetics and Rare Diseases Centre, IRCCS Neuromed, Pozzilli (IS), Italy.; University of Cambridge; Department of Clinical Neurophysiology, Institute of Psychiatry and Naurology, Warsaw, Poland and Dept. of Neurology, University of Ulm, Ulm, Germany.
Background:
The clinical presentation of Juvenile Huntington's Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management.
Aim:
To survey the current use of pharmacological treatments for JHD.
Methods:
Patients were identified through the HD Association, Hospital Doctors and the European Huntington's Disease Network REGISTRY study.
Results:
The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and anti-parkinsonian medications (15/45). 5 patients were taking more than 8 medications.
Conclusions:
The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Huntington Disease l: Introduction
Pharmaceutical Poisoning: Treatment Strategies
Alzheimer's Disease: Treatment
Drug Therapy
Antianxiety Medications
Therapeutic Drug Monitoring: Overview and Classification

